You may be entitled to significant compensation if you developed Cutaneous T-Cell Lymphoma (CTCL) — a rare form of Non-Hodgkin’s Lymphoma (NHL) — or its subtypes Sézary Syndrome or Mycosis Fungoides after receiving Dupixent® (dupilumab).
Patient was treated with Dupixent® for 30 days or more and was diagnosed with CTCL (Cutaneous T-Cell Lymphoma), Sézary Syndrome, or Mycosis Fungoides — forms of Non-Hodgkin’s Lymphoma (NHL).
Medical documentation confirming the diagnosis (e.g., pathology/dermatology/oncology records).
Individuals seeking justice for serious adverse effects following prescribed medication.
| Step | What You Need to Do |
|---|---|
| 1. Complete Our Quiz Form | Answer a few basic questions to see if you qualify. |
| 2. Talk to an Attorney | If eligible, we'll connect you with experienced legal counsel. |
| 3. Potential Compensation | You could be eligible for financial recovery for medical costs, pain and suffering, and more. |
Patients treated with Dupixent for conditions like eczema, asthma, or nasal polyps have reported developing Cutaneous T-Cell Lymphoma (CTCL) — a form of Non-Hodgkin’s Lymphoma (NHL) — and related subtypes including Sézary Syndrome and Mycosis Fungoides. The lawsuit alleges manufacturers did not adequately warn users about these risks despite available medical evidence.
Medical Expertise Required: Proving the link between Dupixent and CTCL (including Sézary Syndrome and Mycosis Fungoides) depends on detailed medical and pathology evidence.
Financial Recovery: You may be entitled to compensation covering medical expenses, lost income, and emotional distress.
No Upfront Costs: Attorneys working on this case typically operate on a contingency basis — you pay nothing unless compensation is recovered.
Dupilumab is a biologic medication approved for treating moderate-to-severe eczema, certain types of asthma, and nasal polyps. Since approval, some patients have reported serious side effects, including diagnoses of CTCL (a form of NHL) and its subtypes Sézary Syndrome and Mycosis Fungoides following treatment.
Cutaneous T-Cell Lymphoma (CTCL) — a rare form of Non-Hodgkin’s Lymphoma involving the skin; subtypes include Mycosis Fungoides and Sézary Syndrome.
Serious dermatologic and hematologic issues potentially misdiagnosed as eczema.
The litigation centers on whether manufacturers should have warned users of these risks prior to widespread prescribing.
Legal claims in this type of drug litigation are governed by statute of limitations and evidentiary requirements. The sooner you speak with an attorney, the better your ability to build a strong claim.
If you or someone you love was treated with Dupixent and subsequently diagnosed with CTCL (a form of NHL), Sézary Syndrome, or Mycosis Fungoides, please take our short eligibility quiz. If your case qualifies, we'll help you connect to legal counsel who specialize in pharmaceutical litigation.
Fill out the form to see if you may qualify. Get the compensation you deserve.
